Haemostasis Management

Treatment of haemophilia patients, both A and B, and patients with other coagulation factor deficiencies is normally based on replacement therapy, this is substitution of the missing clotting factor.

* Source: World Federation of Haemophilia.  Report on the annual global survey 2011.
 

NovoEight® Recombinant Factor VIII Turoctocog alfa Summary (SmPC)
NovoSeven® Recombinant Factor VIIa Eptacog alfa Summary (SmPC)
NovoThirteen® Recombinant Factor XIII-A subunit Catridecacog Summary (SmPC)




 

HQMMA/CD/0115/0022(1)


Novo Nordisk Pro

Novo Nordisk Pro is the official Novo Nordisk online resource exclusively for healthcare professionals.

Go to Novo Nordisk Pro